Analysis
Retension Pharmaceuticals priced an upsized initial public offering of 3,750,000 shares at $12.00 per share, for expected gross proceeds of $45.0 million, according to a company announcement. Shares began trading October 9 on the Nasdaq Capital Market under the ticker RTSN, with underwriters holding a 30-day option on up to 562,500 additional shares.
Pulse covered Retension's second S-1 amendment on October 7. What's changed since then: the company upsized its share count and completed pricing two days later, with Leerink Partners, Guggenheim Securities and Oppenheimer & Co. as joint bookrunners and Titan Partners as lead manager -- moving from a filed amendment to a priced, trading IPO in roughly 48 hours.
“Pulse covered Retension's second S-1 amendment on October 7.”
Net proceeds, combined with existing cash, will fund completion of Retension's Phase 2b trial of RTN-001 in uncontrolled hypertension and prepare for a planned Phase 3 trial. Uncontrolled hypertension remains one of cardiology's more crowded indications, with established combination therapies already on the market, so RTN-001's differentiation will matter more to Retension's post-IPO trading than the size of this raise. The deal's quick turn from amended filing to priced offering stands in sharp contrast to Firmus Technologies' IPO withdrawal the same week -- a reminder that investor appetite for AI infrastructure and for clinical-stage biotech are, right now, moving in different directions.
